MedGenome | About Us
Toll Free Number: 1800 103 3691
Hours: 8:00 AM - 8:00 PM, Monday to Saturday
Closed on public holidays and Sundays

About Us

MedGenome is a genomics and clinical data driven diagnostics and drug discovery research company founded in 2013.

We are the market leader in genetic diagnostics in India and offer comprehensive diagnostic solutions to researchers, doctors & hospitals. We have expertise in simultaneous genome sequencing and clinical data analysis to identify genetic mutations across several disease areas.

We operate the largest College of American Pathologists (CAP) accredited Next Generation Sequencing(NGS) lab in South East Asia housing cutting-edge genome sequencing platforms such as Illumina’s NovaSeq, HiSeq X, HiSeq 4000 and2500, MiSeq, etc.

OUR FOOTPRINT
covers the whole of India and parts of South Asia covering 218 serviceable locations
with over
1600
hospitals
and
more than
8000
clinicians leveraging
our services
We currently offer
more than
1000
genetic testing

across several disease categories such as paediatrics, neurology, oncology, hematology, endocrinology, nephrology, ophthalmology, etc.

Our Expertise

We have a team of molecular biologists, geneticists, data scientists and bioinformaticians who drive our genomics research. We have successfully built research pipelines addressing immune oncology, biomarker discovery, companion diagnostics and population-based genomic studies that tap the rich Indian diverse genotype.

We are the founding member of
GENOMEASIA 100K
an initiative to sequence
200,000+ Genomes
in Asia.
We have worked extensively on building clinical databases of
more than
1 Million
patients through collaborations.
We have a repository of clinical, phenotypic and genomics data for
more than
170,000
patients
to provide insights into complex diseases at the genetic and molecular level.
We have access to data that provides insights into genetic diversity of Indian population for
more than
4,500
population groups.

Innovation

Innovation is a core belief and many of our tests have been developed in-ouse including our comprehensive gene panels. We believe in continuous innovation to help reduce the cost of genetic tests and empower clinicians with actionable clinical insights to provide better outcomes. Our liquid biopsy test OncoTrack for monitoring cancer treatment is the only NGS-based ctDNA test available in India.

We hold several IPs that include Clinical Exome, TB testing, Liquid Biopsy, Tumour Mutation Burden, and many such tests developed for various diseases. We have also launched India centric Carrier Screening Test for couples planning a baby. In the Rare Disease segment, we offer Whole Exome, Clinical Exome and TrioExome sequencing test for identifying gene mutations that cause rare diseases.

MedGenome has entered strategic partnerships to provide best in class tests like Non-Invasive Prenatal Test(NIPT), Infectious Diseases and several other companion diagnostics partnerships with leading pharmaceutical companies.

Accreditations

As a firm believer in quality, MedGenome adheres to the highest international standards when it comes to our services and have obtained the prestigious CAP accreditation for our main lab in Bangalore.

Our Journey

  • Series A
    funding of
    $4m led by Emerge
    Ventures
  • Single gene
    tests - MiSeq
  • Small gene
    panels
  • Exome
    sequencing –
    all genes
  • Gene Panels
  • HiSeq
  • Series B
    funding of
    $20m led by
    Sequoia
  • NIPT – Non
    Invasive
    Prenatal
    testing
  • HLA
    matching –
    for
    transplants
  • Genome Asia
    100k
  • PGS – for IVF
  • Series C1
    funding
    $40m led by
    Sequoia India
    and Sofina,
    Zodius
    Capital &
    HDFC
  • Carrier
    screening test
  • Liquid biopsy
  • CAP
    accreditation,
    Bangalore lab
  • Comprehensive
    (SNVs, CNVs &
    fusions)
  • Solid & liquid
    tumor panels
  • Coronary
    Artery
    Disease
    (Polygenic
    risk score)
  • Infectious
    diseases
    portfolio
    including TB
  • $55m Series
    C2 funding
    led by
    Leapfrog
  • Comprehensive
    TB Portfolio
    (Routine and
    Molecular)
  • ICMR approved
    Lab for Covid
    Testing
  • Series C3
    funding of
    $16.5m led
    by IFC World
    Bank Group
  • Launched
    Personal
    Genomics
    Division -
    Genessense
  • Additional
    Cancer Tests

2013

  • Series A funding of $4m led by Emerge Ventures
  • Single gene tests - MiSeq
  • Small gene panels

2014

  • Exome sequencing – all genes
  • Gene Panels
  • HiSeq

2015

  • Series B funding of $20m led by Sequoia
  • NIPT – Non Invasive Prenatal testing
  • HLA matching – for transplants

2016

  • Genome Asia 100k
  • PGS – for IVF

2017

  • Series C1 funding $40m led by Sequoia India and Sofina, Zodius Capital & HDFC
  • Carrier screening test
  • Liquid biopsy
  • CAP accreditation, Bangalore lab

2018

  • Comprehensive (SNVs, CNVs & fusions)
  • Solid & liquid tumor panels

2019

  • Coronary Artery Disease (Polygenic risk score)
  • Infectious diseases portfolio including TB

2020

  • $55m Series C2 funding led by Leapfrog
  • Comprehensive TB Portfolio (Routine and Molecular)
  • ICMR approved Lab for Covid Testing

2021

  • Series C3 funding of $16.5m led by IFC World Bank Group
  • Launched Personal Genomics Division - Genessense
  • Additional Cancer Tests

Awards and Recognition

Economic Times Healthworld
India Diagnostics Award
Best Standalone
Diagnostics
(South)- 2021
The Healthcare
Technology report
Top 25 Health Technology
CEOs of Asia- 2020
Economic Times Healthworld
India Diagnostics Award
Outstanding Research
in Diagnostics
(National)- 2020
Startup 50 by
Smart CEO -
2019
Asia Red Herring
Top 100 - 2019
Economic Times
Now Rise with India
Making of Developed India
Award - 2017
Business World
Disruptor
Healthcare - 2017

Kokilaben
Dhirubhai Ambani
group - 2017
Indıan Express
India’s Top Emerging
Companies - 2016
Bangalore India Bio
Emerging Company
of the Year - 2016
World CSR and Sustainability
Certificate of Merit
Leadership in advanced
precision medicine in
healthcare- 2015
ABP News
Healthcare leadership
award - 2015

Management

Directors

Sam

Sam Santhosh

Sam Santhosh founded MedGenome in 2013 as a spin-off from SciGenom, which he had founded in 2009. He is a science savvy entrepreneur with close to three decades of experience in launching and running successful businesses. Passionate about science and technology, Sam firmly believes that as technology was the key driver for growth in the latter half of the 20th century, so would be genomics in the 21st century. Through MedGenome, he has transformed the medical genomics and diagnostics space in India and showed path for others to emulate. At MedGenome, he provides strategic direction, oversees business development plans, and helps raise capital for future growth. He is also an investor and mentor for many other companies. Currently, he is an Advisor/Board member at Impelsys Inc, New York, ePay Healthcare, San Francisco, SciGenom Labs, Cochin, AgriGenome, Hyderabad, Emerge Ventures, Singapore, and the Centre for Commercialization of Antibodies (CCAB) Toronto, Canada. Previously, he was the Founder, CEO, and Managing Director of California Software Limited (Calsoft). Sam holds a degree in Engineering from University of Calicut and an MBA from IIM Calcutta. He has attended Executive Education programs at MIT and Singularity University.
Mahesh

Mahesh Pratapneni

Mahesh Pratapneni is the Co-founder and Board Member of MedGenome. He has led strategy, partnerships, and corporate development including fundraising for the company. Mahesh is Founder and MD of Emerge Ventures that specializes in incubating product companies in the education, healthcare, and data/analytics sectors. He is known for building outstanding global teams and comes with broad experience in product visualization, development, management, and building global delivery models. He holds a B. Tech. degree in Electronics and Communications from IIT Madras and an MBA from IIM Calcutta. Mahesh is one of the youngest to be recognized as IIM Calcutta Distinguished Alumnus.
Felix

Dr Felix Olale

Dr Felix Olale is a Partner at LeapFrog and the firm’s Global Co-Leader for Health Investments. He is also an entrepreneur and physician-scientist, renowned for his work building businesses and investing in healthcare in emerging markets. Prior to LeapFrog, Dr Olale was Chairman of the Excelsior Group, a US-Africa based advisor and investor in health and technology companies. Dr Olale was also Senior Advisor to the International Finance Corporation (IFC) for their Health in Africa Initiative. In addition, Dr Olale was co-founder of the Institute for Healthcare Management at Strathmore Business School, and a founding member of Safaricom’s Health Advisory Board. Dr Olale began his career as a physician-scientist at Skirball Institute of Bio-molecular Medicine in New York, where he cloned two genes involved in organ asymmetry and regeneration. He then worked in venture capital with New York University’s Office of Industrial Liaison and Technology Transfer. Later, he was an Associate Partner at McKinsey & Company in New York, where he was a leader in the Pharmaceutical, Medical Products and Global Health practices. Dr Olale holds a Bachelor of Arts (Hons.) in Molecular Biology from the University of Pennsylvania, where he was a University Scholar. He received his Medical Degree and Doctorate from New York University’s School of Medicine. Dr Olale serves as a Board Trustee and Chairman of the Governance Committee for PATH, the leading global health innovator and is a Member of EMPEA’s Africa Council.
Neeraj

Neeraj bhargava

Neeraj is a successful entrepreneur with a decade of experience in the investment industry. He is the founder, CEO, and Senior Managing Director of Zodius Capital Advisors. He is an investor-operator and board member at companies like BigBasket, Allygrow and Markets & Markets. Neeraj is also the CEO and Chairman of Rainshine Entertainment, a next-generation media and entertainment company. Prior to joining Zodius, he had co-founded and led multiple companies including WNS Global Services and eVentures India. Earlier in his career, Neeraj was a partner at McKinsey & Company, where he worked at New York, London, and Mumbai offices, and led practices and client relationships in the technology sector. Neeraj, an alumnus of St. Stephen’s College, Delhi University, India has a BA in Economics.
Tejeshwi Sharma

Tejeshwi Sharma

As a Principal, Tejeshwi Sharma advises on growth stage technology investments for Sequoia in India. He currently serves on the boards of Moglix, Medgenome, Rebel Foods and Whatfix. In the past, Tejeshwi has managed Tencent’s India investments, where he led investment in Byju’s and Dream11. Tejeshwi graduated from the Indian Institute of Technology, Delhi with a bachelor’s in mechanical engineering and holds an MBA from Stanford GSB.

Advisors

Dr. Stephan C Schuster is currently the Research Director and Professor at the Singapore Centre on Environmental Life Sciences Engineering, Nanyang Technical University, Singapore. Dr. Schuster has over 15 years of experience setting up and operating centralized sequencing core labs at Max Plank Institute in Germany and Penn State in the US. He won the Science magazine’s breakthrough of the year award in 2006 (runner-up) and 2008 (Top 10). He was also awarded the Time Magazine’s top ten Scientific discoveries in 2008 and along with W. Miller was among Time magazine’s top 100 most influential people of 2009. His research interests include Metagenomics, Evolutionary Biology, and ancient DNA.

Dr. I. C. Verma is currently the head of the Department of Genetic Medicine at Sri Ganga Ram Hospital, New Delhi. Previously he was a Professor of Pediatrics and Genetics in AIIMS, New Delhi. He received genetics training in the UK, USA, and Switzerland. He is a Fellow of the Royal College of Physicians, London, the American Academy of Pediatrics, and the National Academy of Medical Sciences, New Delhi. He has received a number of national awards – Ranbaxy Science Award, ICMR, NAMS, and BC Roy Medical Council award. He is a Member and Vice-Chairman of the Ethics Committee of the International Human Genome Organization (HUGO) and serves as a genetics adviser for the WHO in Geneva, and to Roche Genetics in Basel. He has vast experience in genetic counseling, serving about 2000 cases with genetic problems every year, and bringing the benefits of genetics and genomics to large number of patients.

Dr. C. N. Ramchand serves as the Chief Executive Officer and President of Saksin Lifesciences Pvt Ltd. and MagGenome Technologies Pvt Ltd. Dr. Ramchand has 30 years of industrial and academic experience in the field of drug discovery, nanotechnology, and nutraceuticals. He has held key leadership positions such as India Director at Kemin Industries, India and Vice President & Head of New Drug Discovery (biological) Research Programme at Sun Pharma Advances Research Centre (SPARC) India. He has also held the position of Joint Co-ordinator and Head, Laboratory Research Program at Biomedical Sciences, University of Sheffield and Northern General Hospital Sheffield, UK, a prestigious University Position. Prior to this he was the Sr. Scientist and Project Head at the Institute of Biological Psychiatry at University of Wales, Bangor, UK. Dr. Ramchand has published over 70 peer-reviewed papers in international journals, edited 5 books and has over 40 patents.

Investors

MEDGENOME VISION IS SUPPORTED BY

Test Menu

Genetic Counselling

Microsites

Collaterals

Contact Us

Test Menu

Genetic Counselling

Microsites

Collaterals

Contact Us